28,539 Shares in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Bought by FORA Capital LLC

FORA Capital LLC acquired a new stake in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) in the fourth quarter, Holdings Channel reports. The institutional investor acquired 28,539 shares of the company’s stock, valued at approximately $156,000.

Other large investors have also modified their holdings of the company. Performa Ltd US LLC raised its holdings in Maravai LifeSciences by 614.3% in the 4th quarter. Performa Ltd US LLC now owns 5,000 shares of the company’s stock worth $27,000 after purchasing an additional 4,300 shares during the period. FNY Investment Advisers LLC raised its stake in shares of Maravai LifeSciences by 600.0% during the 4th quarter. FNY Investment Advisers LLC now owns 7,000 shares of the company’s stock worth $38,000 after buying an additional 6,000 shares during the period. Farther Finance Advisors LLC lifted its position in shares of Maravai LifeSciences by 3,541.4% during the 4th quarter. Farther Finance Advisors LLC now owns 10,196 shares of the company’s stock valued at $56,000 after buying an additional 9,916 shares in the last quarter. Cibc World Markets Corp acquired a new stake in Maravai LifeSciences in the 4th quarter valued at $56,000. Finally, Atria Investments Inc purchased a new stake in Maravai LifeSciences in the 4th quarter worth $58,000. Institutional investors and hedge funds own 50.25% of the company’s stock.

Maravai LifeSciences Stock Performance

Shares of Maravai LifeSciences stock opened at $1.99 on Friday. The business’s 50 day moving average price is $2.17 and its 200 day moving average price is $4.21. The company has a market cap of $506.13 million, a price-to-earnings ratio of -1.21 and a beta of 0.19. The company has a debt-to-equity ratio of 0.89, a quick ratio of 9.94 and a current ratio of 10.74. Maravai LifeSciences Holdings, Inc. has a one year low of $1.67 and a one year high of $11.56.

Analyst Ratings Changes

Several equities analysts have issued reports on MRVI shares. Morgan Stanley decreased their price objective on shares of Maravai LifeSciences from $7.00 to $5.00 and set an “equal weight” rating on the stock in a report on Tuesday, March 25th. Baird R W lowered shares of Maravai LifeSciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 26th. Stifel Nicolaus set a $5.00 price objective on Maravai LifeSciences in a research note on Friday, March 21st. Robert W. Baird downgraded Maravai LifeSciences from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $9.00 to $3.00 in a research report on Wednesday, February 26th. Finally, UBS Group dropped their price target on Maravai LifeSciences from $8.00 to $2.50 and set a “neutral” rating for the company in a research report on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $6.34.

Maravai LifeSciences Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.